Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma.
Santini D, Santoni M, Conti A, Procopio G, Verzoni E, Galli L, di Lorenzo G, De Giorgi U, De Lisi D, Nicodemo M, Maruzzo M, Massari F, Buti S, Altobelli E, Biasco E, Ricotta R, Porta C, Vincenzi B, Papalia R, Marchetti P, Burattini L, Berardi R, Muto G, Montironi R, Cascinu S, Tonini G.
Santini D, et al. Among authors: maruzzo m.
Oncotarget. 2016 May 31;7(22):33381-90. doi: 10.18632/oncotarget.8302.
Oncotarget. 2016.
PMID: 27027342
Free PMC article.